Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

08 févr. 2024 09h10 HE | Source: SK Biopharmaceuticals Co., Ltd.

SK Life Science Labs Experts Unveil Latest Scientific Findings at Keystone Symposia on Epigenetic Mechanisms and Cancer Treatment, and the 2nd Annual Molecular Glue Drug Development Summit

KING OF PRUSSIA, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- SK Life Science Labs (formerly Proteovant Therapeutics) a subsidiary of SK Biopharmaceuticals, Co., Ltd., showcased its cutting-edge targeted...
31 oct. 2023 09h00 HE | Source: SK Biopharmaceuticals Co., Ltd.

SK Life Science Labs, a Subsidiary of SK Biopharmaceuticals, Presents Discovery of Oral SMARCA2 Degraders Data at 6th Annual Targeted Protein Degradation Summit

KOREA and KING OF PRUSSIA, Pa., Oct. 31, 2023 (GLOBE NEWSWIRE) -- SK Life Science Labs (formerly Proteovant Therapeutics) a subsidiary of SK Biopharmaceuticals, today will present preclinical data...
12 oct. 2023 13h00 HE | Source: SK Biopharmaceuticals Co., Ltd.

SK Biopharmaceuticals’ Proteovant Therapeutics Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

KOREA and KING OF PRUSSIA, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- SK Biopharmaceuticals, a global biotech focused on the research, development and commercialization of treatments for disorders of...
26 sept. 2023 10h01 HE | Source: SK Biopharmaceuticals Co., Ltd.

SK Biopharmaceuticals’ Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and MOPED™ Molecular Glue Screening Platform at the 20th Annual Discovery on Target Conference

KOREA and KING OF PRUSSIA, Pa., Sept. 26, 2023 (GLOBE NEWSWIRE) -- SK Biopharmaceuticals, a global biotech focused on the research, development and commercialization of treatments for disorders of...